Ce contenu a 22 ans. Merci de lire cette page en gardant son âge et son contexte en tête.

Contact: Gaëlle Krikorian: + 33 6 09 17 70 55/ 658 520 872 (Barcelona local number)

Almost 10 000 people die of AIDS every day.

Today we know how to fight the epidemic; we know that HIV-infected people in developing countries are not doomed, but can be kept alive; we know what treatments to implement.

And yet, the epidemic keeps spreading; every year millions of people are infected and die.

There is only one explanation for this state of things : world leaders refuse to invest the necessary funds.

One year ago the G8 countries and the Member States of the United Nations acknowledged it was necessary to spend a minimum of ten billions dollars a year to fight AIDS and committed themselves to providing this amount.

Today one question on everyone’s mind is : where is the 10 billion dollars?

There are solutions

When multitherapies were launched six years ago and sick people asked for access to antiretrovials everywhere in the world, the reaction of donors was the same : they were unanimous in rejecting such a request which they
considered unacceptable, utopian and demagogic.

Throughout the years we removed obstacles one after the other:

– It is now at last recognized that an efficient policy to fight the epidemic combines treatment and prevention, and that excluding one of these two components for economic reasons turns out to be a disaster not only in terms of public health, but also in terms of economic development.

The opinion that only prevention measures could stem the epidemic prevailed for twenty years : it led to the infection and deaths of millions of people.
Experts are absolutely sure : an efficient form of prevention requires people becoming aware of the disease and therefore getting medical care.
Right now only antiretrovirals fight the virus and keep people alive; they fundamentally change our approach to the disease.

But twenty years of self-deception and miserliness have elapsed with millions of people dying and the epidemic relentlessly spreading in size and scope, before the wisdom of worn-out clichés which determined our way of
thinking and acting, was challenged.

– NGOs and HIV researchers have proved access to antiretroviral treatments is feasible in resource-poor countries.

Medical care with antiretrovials is possible; molecules are naturally just as effective for people in developing countries as for people in developed countries; the patients who are being treated with antiretrovirals perfectly comply with the treatment regimens if they understand their future is at stake.

Since multitherapies were launched, international donors have been claiming that the cost of such medicines is too high for them to pay for the medical care of people living with HIV/AIDS in poor countries.

For two years, however, generic copies of particularly expensive antiretrovirals have been produced in developing countries by public institutions (Brazil, Thailand) or private companies (India) and sold at much lower prices than those of brand-name drugs by patent holders.

In October 2000 an Indian producer launched a generic tritherapy for $ 800 a year, which represented a saving of more than 90% in comparison with the prices of multinational corporations. In February 2001 his price dropped to $350. In October 2001 the price of another producer came down to $295. Right now the lowest prices are close to $200.

The marketing of these low-cost generic drugs immediately resulted in Big Pharma adjusting its own prices despite the fact that until then it had adamently refused to accede to the entreaties of UN agencies and grant significant price reductions to developing countries.

Thus the marketing of generic antiretrovials has proved two things:

– that medicines can be sold at prices much lower than those of western pharmaceutical companies( we do not know the marginal costs of production yet, but they must undoubtedly be lower than the prices of generic producers)

-that generic competition is the most efficient means to get a drastic and lasting reduction in the prices of medicines. Such competition is much more persuasive and efficient than occasional charitable donations by patent holders enjoying a monopoly situation.

Last december, during the Internationale Conference of WTO in Doha, the 142 Member States signed on a declaration recognizing the right for the countries to produce and import low cost generic drugs.

Now all patients should have access to these medications; countries should be able to buy large quantities of generics.


The G8 countries must immediately
commit to devoting O.O5%

at least of their GNP to the
funding of the fight against AIDS.
The WHO must be the spearhead
of the promotion campaign of anti-AIDS generic medicines:

For medicines to become affordable, several measures
have to be taken:

-developing bulk procurement at the international
as well as the regional level in order to be able to negotiate better prices
on the basis of bulk purchasing of medicines;

-increasing production capacity and transfer
of technology to encourage local production in developing countries;

-issuing compulsory licences to make it possible
to produce and import generic medicines;

-resorting to parallel importation;

-and generally speaking,encouraging systematic
competition between brand-name and generic medicines.

Access to generics is of fundamental importance
for developing countries and the only long-term prospect of having access
to the widest range of treatments at the lowest prices.

The WHO must not embroil developing countries
in partnerships with private companies, such as Accelerating access, without
guaranteeing the negotiation framework is transparent, ethical principles
are respected and some results are achieved. The WHO must urgently 
review its policy and develop a strategy based above all on competition
among producers.

The WHO must be able to provide countries with
the most exhaustive information possible on suppliers of anti-AIDS medicines
as well as their prices, and necessarily include generics producers.

The WHO must speed up the process of endorsing
generic medicines to ease access to them in developing countries.

The WHO must provide developing countries with
expertise and technical support to help them devise their legislation on
intellectual property, incorporating the flexible provisions of the TRIPS
Agreement and the Doha Declaration to have access to generics.

The WHO must support countries trying to develop
bulk procurement of medicines at the best prices possible as well as local
production and tranfer of technology.

The WHO must provide developing countries wishing
to set up national access programs for antiretroviral treatment with genuinely
adequate technical aid.


Today the key issue is to rapidly scale up access to medicines in developing countries, to increase the number of health care centers and make it
possible for many more people to have access to treatments in the countries where only a few hundred people are being treated.

World leaders are responsible for the disaster

Since the prices of medicines can be significantly reduced, nothing should prevent rich countries from undertaking to fund bulk purchasing of treatments and the strengthening of health care structures in order to widen access to medicines for people with AIDS in poor countries.

Yet, the necessary funds are not available.

In april 2001 at the African Summit on HIV/AIDS, tuberculosis and other infectious diseases in Abuja, Kofi Annan announced the creation of a Global
Fund with an annual commitment of 10 billion dollars to fight AIDS, and declared: « It is unacceptable that the poorest sick people cannot have access to medicines that have changed the lives of sick people in rich countries.»

One year later, despite the pledges of the Member States of the United Nations in June 2001 and of the G8 countries in July 2001, the proposed 2002 funding does not reach 2.08 billion dollars and the funds disbursed this year will reach only 700 to 800 million dollars.

At UNGASS last June in New York and then at the Genoa meeting of the G8 heads of state in July, developed countries committed themselves to funding the Glabal Fund.

Sick people in developing countries, NGOs and activists may have believed then that the Global Fund was going to be a major turning point in the fight
against the epidemic : to enable at last to scale up funding and treatment programs.

However, the present funding commitment shows that international donors and political leaders hedge pledges to fight AIDS.
Moreover, they are still reluctant to fund medicines. Thus, Richard Feachem, the executive director of the Global Fund,is unaware of or denies the real situation, the vast needs of people living with HIV/AIDS in developing countries, and refuses to consider purchases of antiretroviral medications a priority.

Thus if the epidemic keeps killing millions of sick people every year, if millions of people get infected every year, it is above all because international donors refuse to invest the necessary funds to stop the scourge.

Today in Barcelona, the question which is raised and remains unanswered is:
where is the ten billion dollars?


AIDS and G8 :

Where is the 10 billion dollars?

A year after the Group of Eight Industrialized
Countries announced the « historic » creation of a Global Fund to fight AIDS,
the contribution of the richest countries does not reach one tenth of the
goal set forth by Annan.

Where is the ten billion dollars? There is
almost no money left in the coffers of the Fund. In the past 12 months
almost 3 million people have died of AIDS and the epidemic continues expanding
in size and scope.

In 2000 and more than 15 years after the beginning
of the epidemic, the UN Security Council followed by the US Security Council
announced that the AIDS pandemic was one of the most serious threats to
world stability.

A few months later the World Bank warned the international
community that the devastating effects of the epidemic in poor countries
were about to annihilate 50 years of development. Then Jeffrey Sachs, the
head of the Harvard Institute in charge of the Health and Macroeconomic
Commission of the WHO, published an expert report estimating the funds
necessary to control the pandemic at 10 billion dollars a year ­ a
mere 0.05% of the GNP of the 8 richest countries, and less than what the
G8 countries keep collecting from poor countries as debt service.

In April 2001 at the Abuja Summit in Nigeria,
Kofi Annan, the UN Secretary General, called for an international financial
mobilisation « without any common measure with the resources we presently
spend if we want to win the war against AIDS ». The UN General Assembly
Special Session on HIV/AIDS adopted the same target of 10 billion dollars
a year. Thus in July 2001, in Genoa, the 8 richest states announced the
creation of a Global Fund to finance the global war on aids.

To date their contributions do not add up to 500
million dollars a year, that is less than 5% of the target. Where is the
10 billion dollars? In the last 12 months almost 3 million people have
died of AIDS. By 2015, if the trend is not reversed, 100 million people
will be infected with HIV/AIDS and 95 million will eventually die.

Throughout the years, grass-roots activists, people
with HIV, NGOs and doctors have mobilised day after day to fight the epidemic
and save infected people. However, without more funds they will lose the

The G8 industrialized countries bear responsibility
for the deaths of 10,000 persons every day; responsibility for the continuous
expansion of the epidemic which threatens the development and stability
of entire continents.

This is why the G8 countries must immediately
commit to devoting O.O5% at least of their GNP to the funding of the fight
against AIDS.